Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Autologous bone marrow transplantation

A K Fielding1, A H Goldstone

  • 1Department of Haematology, University College London Hospitals, UK.

Current Opinion in Hematology
|November 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.

Bone marrow transplantation·2021
Same author

The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

Bone marrow transplantation·2017
Same author

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Blood cancer journal·2016
Same author

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial.

Leukemia·2016
Same author

Autologous Bone-Marrow Transplantation in Acute Lymphoblastic Leukaemia: 1980-89.

Leukemia & lymphoma·2016
Same author

Systemic Irradiation Therapy of Myelomatosis-The Therapeutic Implications of Technique.

Leukemia & lymphoma·2016

High-dose chemotherapy with autologous stem cell support is a growing treatment for malignant diseases. However, limited randomized clinical data exist to confirm its survival benefits, especially for myeloma and solid tumors.

Area of Science:

  • Oncology
  • Hematology

Background:

  • High-dose chemotherapy with autologous stem cell support is increasingly utilized for malignant diseases.
  • Peripheral blood stem cells are increasingly preferred, potentially reducing procedure toxicity.
  • Current evidence relies heavily on retrospective analyses, lacking robust clinical trial data.

Purpose of the Study:

  • To evaluate the efficacy and role of high-dose chemotherapy with autologous stem cell support in malignant diseases.
  • To address the scarcity of randomized controlled trials in this therapeutic area.
  • To clarify the survival benefit of high-dose therapy, particularly in myeloma and solid tumors.

Main Methods:

  • Review of existing literature, focusing on randomized controlled trials.
  • Analysis of retrospective studies to identify trends and limitations.

Related Experiment Videos

  • Assessment of data regarding the use of peripheral blood stem cells versus other sources.

    • Main Results:

    • Limited randomized controlled trial data are available to guide clinical practice.
    • Retrospective analyses dominate the literature but do not definitively establish survival benefits.
    • Enthusiasm for high-dose therapy in myeloma and solid tumors outpaces supporting clinical evidence.

    Conclusions:

    • There is a critical need for more high-quality randomized controlled trials to establish the role and efficacy of high-dose chemotherapy with autologous stem cell support.
    • The survival benefit of this treatment modality, especially in specific cancers like myeloma and solid tumors, remains uncertain.
    • Clinical decision-making should be informed by the current lack of definitive evidence from controlled studies.